Search | Page 12 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Myelodysplastic syndromes in older adults.

    ... the drugs lenalidomide , decitabine , and azacitidine have offered treatment options to patients ineligible for ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes.

    ... such as decitabine (5-aza-deoxycytidine) and 5- azacitidine , have led to the expansion of the therapeutic arsenal for MDS. ... and head-to-head comparison studies of decitabine and 5-azacitidine will provide valuable pre-clinical and clinical data, enhancing ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Current and future management options for myelodysplastic syndromes.

    ... of US FDA-approved agents such as lenalidomide , azacitidine and decitabine . Prior to these developments, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. An update on the treatment of myelodysplastic syndromes.

    ... with del(5q), and two different hypomethylating agents, azacitidine and decitabine , are approved for intermediate-2- and ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Pharmacotherapy of myelodysplastic syndromes.

    ... the past decade, response to the hypomethylating agents azacitidine and decitabine in non-del(5q) MDS patients remains at ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.

    ... agents currently approved in the United States-- azacitidine or decitabine --to patients with aggressive forms of ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents.

    ... are well tolerated in outpatient settings, with azacitidine prolonging survival and decreasing time to acute myeloid ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Myelodysplastic syndromes.

    ... the median survival is 2.5 years. Lenalidomide , azacitidine , and decitabine are all FDA-approved agents to treat ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Decitabine treatment of patients with higher-risk myelodysplastic syndromes.

    ... the relative merits of decitabine compared with azacitidine , the optimal decitabine dose and schedule, how best to proceed ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Validation of the revised international prognostic scoring system in treated patients with myelodysplastic syndromes.

    ... Among high and very-high IPSS-R patients receiving azacitidine , OS was significantly improved versus patients not receiving azacitidine, with corresponding median OS of 25 versus 18 months (P=0.023) and ...

    Research Article last updated 05/14/2013 - 2:50pm.